Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Amortizatization of Intangibles: 2014-2024

Historic Amortizatization of Intangibles for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to $6.4 million.

  • Axsome Therapeutics' Amortizatization of Intangibles rose 0.06% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 0.27%. This contributed to the annual value of $6.4 million for FY2024, which is 0.27% up from last year.
  • As of FY2024, Axsome Therapeutics' Amortizatization of Intangibles stood at $6.4 million, which was up 0.27% from $6.4 million recorded in FY2023.
  • Axsome Therapeutics' Amortizatization of Intangibles' 5-year high stood at $6.4 million during FY2024, with a 5-year trough of $786,750 in FY2020.
  • Over the past 3 years, Axsome Therapeutics' median Amortizatization of Intangibles value was $6.4 million (recorded in 2023), while the average stood at $5.6 million.
  • Data for Axsome Therapeutics' Amortizatization of Intangibles shows a peak YoY soared of 284.31% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Axsome Therapeutics' Amortizatization of Intangibles stood at $786,750 in 2020, then soared by 36.89% to $1.1 million in 2021, then surged by 284.31% to $4.1 million in 2022, then soared by 54.02% to $6.4 million in 2023, then climbed by 0.27% to $6.4 million in 2024.